Short Interest in Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR) Decreases By 69.4%

Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR) was the target of a significant decrease in short interest in the month of May. As of May 29th, there was short interest totaling 85,189 shares, a decrease of 69.4% from the May 14th total of 278,140 shares. Based on an average trading volume of 417,303 shares, the days-to-cover ratio is presently 0.2 days. Currently, 3.3% of the company’s shares are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cuprina Holdings (Cayman) in a research note on Friday, April 24th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Cuprina Holdings (Cayman) has a consensus rating of “Sell”.

Cuprina Holdings (Cayman) Trading Up 64.7%

Shares of CUPR traded up $1.56 during trading hours on Friday, hitting $3.97. 83,240,193 shares of the stock traded hands, compared to its average volume of 294,691. Cuprina Holdings has a 1-year low of $1.76 and a 1-year high of $76.00. The firm has a fifty day simple moving average of $2.54. The company has a quick ratio of 2.35, a current ratio of 2.35 and a debt-to-equity ratio of 0.07.

Cuprina Holdings (Cayman) (NASDAQ:CUPR) last released its earnings results on Monday, April 27th. The company reported ($0.40) earnings per share for the quarter. The business had revenue of $0.01 million during the quarter.

About Cuprina Holdings (Cayman)

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. We believe we will be able to build upon and leverage such expertise to develop innovative cosmeceutical products in the future.